Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 20:40:e02233.
doi: 10.1016/j.idcr.2025.e02233. eCollection 2025.

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin

Divya Chandramohan  1 , Samantha Aguilar  2 , Gerard Gawrys  2 , Nathan P Wiederhold  3 , Kristi Traugott  2 , Thomas F Patterson  1
Affiliations
Case Reports

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin

Divya Chandramohan et al. IDCases. .

Abstract

Antifungal resistance in Candida glabrata can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves. Herein we present a case of recurrent fungemia with C. glabrata in a middle-aged woman with Tetralogy of Fallot who had a right ventricle to pulmonary artery conduit, and a transcatheter pulmonary valve replacement in the past. Her isolate showed increasing minimum inhibitory concentrations (MIC) to various antifungals with higher MICs to azoles, including resistance to fluconazole, resulting in limited treatment options. She had affliction of her prosthetic pulmonic valve with C. glabrata and was treated with the second-generation echinocandin, rezafungin, for six months. This case illustrates the tolerability profile of long-term treatment with rezafungin.

Keywords: Candida glabrata; Congenital heart disease infections; Echinocandin; Endocarditis; Recurrent Candidiasis; Resistance mechanisms; Rezafungin.

PubMed Disclaimer

Conflict of interest statement

Patterson TF: Received research support to University of Texas Health San Antonio, TX or has served as a consultant to Basilea Pharmaceutica, Cidara Therapeutics, Inc., Elion Therapeutics, F2G Ltd, Gilead Sciences, Inc., and SCYNEXIS, Inc.

References

    1. Thompson G.R., 3rd, Jenks J.D., Baddley J.W., Lewis J.S., 2nd, Egger M., Schwartz I.S., et al. Fungal endocarditis: pathophysiology, epidemiology, clinical presentation, diagnosis, and management. Clin Microbiol Rev. 2023;36(3) doi: 10.1128/cmr.00019-23. Epub 2023 Jul 13. PMID: 37439685; PMCID: PMC10512793. - DOI - PMC - PubMed
    1. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. PMID: 26679628; PMCID: PMC4725385. - DOI - PMC - PubMed
    1. Meena D.S., Kumar D., Agarwal M., Bohra G.K., Choudhary R., Samantaray S., et al. Clinical features, diagnosis and treatment outcome of fungal endocarditis: a systematic review of reported cases. Mycoses. 2022;65(3):294–302. doi: 10.1111/myc.13398. Epub 2021 Dec 3. PMID: 34787939. - DOI - PubMed
    1. Vieceli T., Giordani B.M., Azeredo de Magalhães G., Serena G.C., Rodrigues Aquino V., Borges V.S., et al. Candida infective endocarditis in patients with Candida spp. bloodstream infection: risk factors and 1- year mortality. Mycoses. 2025;68(2) doi: 10.1111/myc.70032. - DOI - PubMed
    1. Lexicomp Online, Pediatric and neonatal lexi-drugs online. Waltham, MA: UpToDate, Inc.; July 30, 2021. 〈https://online.lexi.com〉 [Accessed 22 May 2024].

Publication types

LinkOut - more resources